First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
暂无分享，去创建一个
R. Pazdur | B. Rellahan | P. Cortazar | G. Blumenthal | R. Justice | Shenghui Tang | A. Ibrahim | N. Scher | Somesh Chattopadhyay | P. Song | Qi Liu | Kimberly Ringgold | A. Pilaro | A. Tilley | K. E. King | L. Graham | W. Weinberg | Bo Chi | C. Thomas | Patricia Hughes | B. Chi | Amy Tilley